Company Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1α, IL-1β-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation.
Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
The company was incorporated in 2015 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| IPO Date | May 24, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Sanj Patel |
Contact Details
Address: 23 Old Bond Street, Floor 3 London, WIS 4PZ United Kingdom | |
| Phone | 781 431 9100 |
| Website | kiniksa.com |
Stock Details
| Ticker Symbol | KNSA |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730430 |
| CUSIP Number | G5269C101 |
| ISIN Number | BMG5269C1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
| Mark A. Ragosa C.F.A. | Senior Vice President and Chief Financial Officer |
| Eben Tessari | Executive Vice President and Chief Operating Officer |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Ross Michael Moat | Executive Vice President and Chief Commercial Officer |
| Michael R. Megna CPA | Chief Accounting Officer and Group Vice President of Finance |
| Mei Jang | Senior Vice President of Technical Operations |
| Jonathan Kirshenbaum | Investor Relations Officer |
| Chad Morin | Senior Vice President and Chief Compliance Officer |
| Madelyn Demsky Zeylikman | SVice President, General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 7, 2025 | 144 | Filing |
| May 7, 2025 | 144 | Filing |
| May 7, 2025 | 144 | Filing |
| May 5, 2025 | 144 | Filing |
| May 2, 2025 | 144 | Filing |
| May 1, 2025 | 144 | Filing |
| May 1, 2025 | 144 | Filing |
| Apr 30, 2025 | 144 | Filing |
| Apr 29, 2025 | 144 | Filing |